Beta blocker choice may improve heart outcomes on dialysis
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This phase 3 study tests whether a specific beta blocker selection on hemodialysis can improve cardiovascular outcomes. It focuses on certain beta blockers commonly used through the VA pharmacy and compares them in a randomized way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving hemodialysis (dialysis through a machine)
- You currently take one of these VA pharmacy beta blockers: metoprolol, atenolol, labetalol, carvedilol, or bisoprolol
- You (or someone legally allowed to make decisions for you) can give consent
- You do not have a history of bad allergic reactions to either study medication
- Your care team agrees to sign a new medication order if you are randomized
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two beta-blocker medications, carvedilol and metoprolol succinate, to see which one works better for people with heart failure who have an implantable cardioverter defibrillator (ICD). If you are currently taking metoprolol succinate, you may be able to switch to carvedilol and help researchers find the best treatment.
This study tests an investigational drug (RVX000222) to see if it helps people with kidney failure who are on dialysis. The drug is given in two parts and may help improve heart health, which is often a concern for dialysis patients.
This study tests whether safely stopping beta-blocker heart medications can help older adults with a type of heart failure where the heart pumps normally but is stiff. Participants will be followed to see how stopping the medication affects their symptoms and health.
This trial tests whether a genetic test can help doctors choose the best beta blocker for people with heart failure who have mildly reduced pumping function. It aims to improve treatment by matching the drug to your genetic profile.
This study compares two blood pressure medications (spironolactone and chlorthalidone), given alone or in combination, to see if they help protect kidneys in people with chronic kidney disease and high blood pressure. The goal is to find a better way to slow kidney decline.
This study compares two heart medicines, carvedilol and metoprolol succinate, for people with a certain type of heart failure. It aims to see if they work just as well as each other.
Hear when a new End Stage Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.